Connect Biopharma Holdings Limited Ordinary Shares CNTB
$2.04
-0.97%
at last close
Market Cap$129.73 million
P/E Ratio—
Div Yield—
Volume840.0K
52-Week Range
$1.23$3.82
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $7.29 (+257.1% upside)
Key Stats
- Today's Range
- $1.94 – $2.10
- 50-Day Range
- $1.74 – $2.93
- 52-Week Range
- $1.23 – $3.82
- Volume
- 840K shs
- Average Volume
- 810K shs
- Market Cap
- $129.73 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.83
- Price / Sales
- 43.93
Short Interest
- Short Interest
- 1.23%
- Days to Cover
- 1.64
Financials (TTM)
- Revenue
- $2.95 million
- Net Income
- $-68,991,000
- Net Margin
- -2336.30%
- Return on Equity
- -256.84%
- Debt-to-Equity
- —
About Connect Biopharma Holdings Limited Ordinary Shares
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Related Stocks
Compare head-to-head: CNTB vs LLY·CNTB vs JNJ·CNTB vs ABBV·CNTB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.